Physiomics Plc (AIM:PYC)

Market Cap	2.04M +58.3%
Revenue (ttm)	1.06M +26.5%
Net Income	-697.03K
EPS	-0.00
Shares Out	453.21M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,002,172
Open	0.4500
Previous Close	0.4750
Day's Range	0.4500 - 0.5000
52-Week Range	0.2500 - 0.8000
Beta	1.03
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 16, 2026

About Physiomics

Physiomics Plc provides consulting services to pharmaceutical companies in the areas of outsourced quantitative pharmacology and computational biology in the United Kingdom, the United States, and the European Union Switzerland. The company offers modeling, simulation, and data analysis services covering various ranges of oncology research and development using its proprietary Virtual Tumour predictive software. It also develops technology for use in the field of personalized medicine. Physiomics Plc was incorporated in 2001 and is based in Oxf...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2001
• Employees: 10
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: PYC

Financial Performance

In fiscal year 2026, Physiomics's revenue was 1.06 million, an increase of 26.50% compared to the previous year's 834,156. Losses were -697,034, 67.9% more than in 2025.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 16, 2026

Data Sources Report a data error